Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COPD patients on dupilumab tracked for 3 years in new study

NCT ID NCT07380711

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 500 adults with COPD who are already taking dupilumab as part of their regular care. Researchers will collect health information over 3 years to see how patients are doing and check for any side effects. The goal is to learn more about the real-world effects of long-term dupilumab treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It is planned to recruit 350 to 500 participants, in up to 50 sites in France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients willing and able to sign informed consent for use of their pseudonymized clinical data within the present non-intervention study. * Adult patients. * Patients with uncontrolled Chronic Obstructive Pulmonary Disease (COPD) despite long-acting muscarinic antagonist (LAMA)/ Long-acting beta2-agonist (LABA)/ Inhaled Corticosteroid (ICS) (or LAMA/LABA if ICS are not appropriate) therapy and elevated blood eosinophils (a blood eosinophil count ≥ 300 cells/microL). * Patients newly initiated on dupilumab treatment as indicated in the dupilumab summary of product characteristics (SmPC) in the specified label for COPD, determined by the treating physician, and independent of participation in the non-interventional study (NIS). Exclusion Criteria: * Patient not eligible for dupilumab treatment according to SmPC. * Participation in an ongoing interventional study or participation in an interventional study up to 12 months before enrolment that might, in the treating physician's opinion, influence the assessments for the current study. * Any acute or chronic condition that, in the treating physician's opinion, would limit the patient's ability to complete questionnaires or to participate in this study or impact the interpretation of the results. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    22 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number : 2500001

    RECRUITING

    Pessac, 33604, France

  • Investigational Site Number : 2500002

    RECRUITING

    Montpellier, 34090, France

  • Investigational Site Number : 2500009

    RECRUITING

    Colmar, 68024, France

  • Investigational Site Number : 2500010

    RECRUITING

    Vantoux, 57070, France

  • Investigational Site Number : 2500017

    RECRUITING

    Paris, 400026, France

  • Investigational Site Number : 2500020

    RECRUITING

    Le Chesnay, 78157, France

  • Investigational Site Number : 2500021

    RECRUITING

    Aix-en-Provence, 13616, France

  • Investigational Site Number : 2500022

    RECRUITING

    Juan-les-Pins, 06600, France

  • Investigational Site Number : 2500024

    RECRUITING

    Marseille, 13003, France

  • Investigational Site Number : 2500026

    RECRUITING

    Nîmes, 30029, France

  • Investigational Site Number : 2500028

    RECRUITING

    Toulouse, 31059, France

  • Investigational Site Number : 2500029

    RECRUITING

    Toulouse, 31076, France

  • Investigational Site Number : 2500031

    RECRUITING

    Contamine-sur-Arve, 74130, France

  • Investigational Site Number : 2500033

    RECRUITING

    Lyon, 69008, France

  • Investigational Site Number : 2500034

    RECRUITING

    Pierre-Bénite, 69495, France

  • Investigational Site Number : 2500035

    RECRUITING

    Villeurbanne, 69100, France

  • Investigational Site Number : 2500038

    RECRUITING

    Libourne, 33500, France

  • Investigational Site Number : 2500040

    RECRUITING

    Niort, 79021, France

  • Investigational Site Number : 2500043

    RECRUITING

    Blois, 41016, France

  • Investigational Site Number : 2500044

    RECRUITING

    Brest, 29200, France

  • Investigational Site Number : 2500047

    RECRUITING

    Morlaix, 29600, France

  • Investigational Site Number : 2500048

    RECRUITING

    Saint-Pierre, 97448, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.